The use of cannabidiol (CBD) in pain reduction for knee osteoarthritis. A Double-Blind Randomized Control Study

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Knee Arthritis
  • Age: Between 40 - 75 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients presenting with knee osteoarthritis (KL Grade II-III)
    2. Knee pain for at least three months, occurring in at least half of the days in that period
    3. VAS = 4
    4. If female patients are pre-menopausal they must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly
    5. Male patients must be using an effective form of contraception

You may not be eligible for this study if the following are true:

    1. Injections within the last 3 months
    2. Legally incompetent or mentally impaired (e.g., minors, Alzheimer’s subjects, dementia, etc.)
    3. Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners
    4. History of cannabis abuse or dependence
    5. History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values
    6. History of stroke or acute coronary syndromes within 3 months
    7. Abnormal coagulation profile
    8. Renal failure or liver cirrhosis
    9. Patients that have been on prior opioid management for OA of the knee
    10. Opioid dependence
    11. Patients with known inflammatory arthritis
    12. Patients with a large effusion
    13. Patients with a BMI > 35
    14. Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder
    15. Patients diagnosed with major depression, psychosis, or substance abuse disorder
    16. Patients with current or a history of suicidal ideation
    17. Breastfeeding females
    18. Patients with clinically significant illness, including cardiovascular disorders
    19. Clinically significant lab abnormalities
    20. Patients with major neurological disorders, such as dementia, Parkinson’s disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures
    21. Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C)

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.